Keywords: dyax, up, 500m, deal, sanofi, drug, discovery
Dyax in up to $500M deal with Sanofi
Article | 18 February 2008
US drug discovery firm Dyax has granted exclusive worldwide rights for the development and commercialization of its fully-human monoclonal antibody ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Is the diabetes market facing a blockbuster-free future?
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
